Please login to the form below

Not currently logged in
Email:
Password:

Otsuka Pharmaceutical

This page shows the latest Otsuka Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Otsuka joins forces with IBM for Watson-based digital venture

Otsuka joins forces with IBM for Watson-based digital venture

Otsuka joins forces with IBM for Watson-based digital venture. Otsuka Digital Health will develop software to analyse psychiatric patient data. ... The venture will operate independently of Otsuka's pharmaceutical business, where its CNS interests, where

Latest news

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    FDA knocks-back Otsuka's digital pill plans. Wants more data on its combination of Abilify and Proteus sensor and pill. ... Robert McQuade, executive vice president and chief strategy officer, Otsuka Pharmaceutical Development &Commercialisation, said:

  • Otsuka expands CNS presence with Avanir purchase Otsuka expands CNS presence with Avanir purchase

    Otsuka expands CNS presence with Avanir purchase. Deal for US biotech is valued at $3.5bn. ... Japan-based Otsuka Pharmaceutical has agreed to buy the California biotech Avanir for $3.5bn, expanding its business in diseases of the central nervous system

  • Otsuka launches European ADPKD forum Otsuka launches European ADPKD forum

    Otsuka launches European ADPKD forum. Aims to lead awareness raising plans for rare genetic condition. ... Otsuka Pharmaceutical Europe has launched a European forum to help lead awareness of the rare genetic condition autosomal dominant polycystic

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    Otsuka wins approval for TB drug Deltyba. Second drug approved by EC in 2014 for multidrug resistant tuberculosis. ... Otsuka Pharmaceutical's Deltyba has become the second medicine approved this year in the EU to treat multidrug resistant (MDR) forms of

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Otsuka Pharmaceutical is developing delamanid, a nitro-dihydroimidazo-oxazole derivative, for use as an oral anti-TB agent. ... Otsuka expects a decision from the European Commission in early 2014.

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Tools for the digital world Tools for the digital world

    In May Proteus and Otsuka Pharmaceutical Co resubmitted a New Drug Application for the drug-device combination product of Ablify (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet.

  • Deal Watch February 2016 Deal Watch February 2016

    AstraZeneca, Sanofi and Otsuka divested or out-licensed rights to products in certain territories. ... Otsuka Pharmaceutical/ Medimetriks Pharmaceuticals. OPA-15406, topical PDE-4 inhibitor for the treatment of atopic dermatitis (pII).

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. †† Ariad Pharmaceuticals / Otsuka

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    265.3. Takeda Pharmaceutical/ Otsuka Pharmaceutical. Co-promotion. TAK-438 (vonoprazan fumarate) for acid-related diseases (NDA filed JP). ... 22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐ endoglin antibodies, including

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • NanoValent promotes Mark Lewis to COO NanoValent promotes Mark Lewis to COO

    He has worked at a number of pharmaceutical firms including Amersham International (now GE), Chiron (now Novartis) and Farmitalia (now Pfizer). ... Most recently, Lewis served as managing director for Europe at SuperGen (now Otsuka Pharmaceutical)

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics